Wedbush restated their outperform rating on shares of Blueprint Medicines Corp. (NASDAQ:BPMC) in a research note released on Tuesday. The brokerage currently has a $41.00 target price on the stock.

Other analysts have also recently issued reports about the stock. Canaccord Genuity set a $35.00 target price on shares of Blueprint Medicines Corp. and gave the stock a buy rating in a report on Saturday, November 12th. Zacks Investment Research upgraded shares of Blueprint Medicines Corp. from a hold rating to a buy rating and set a $27.00 price target for the company in a research report on Thursday, August 11th. Finally, Cowen and Company restated a buy rating on shares of Blueprint Medicines Corp. in a research report on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $32.43.

Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) opened at 30.34 on Tuesday. The stock’s market capitalization is $828.07 million. The company’s 50-day moving average is $32.05 and its 200-day moving average is $25.27. Blueprint Medicines Corp. has a 12 month low of $13.04 and a 12 month high of $38.33.

Blueprint Medicines Corp. (NASDAQ:BPMC) last issued its earnings results on Thursday, November 10th. The company reported ($0.62) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.17. The firm earned $6.16 million during the quarter, compared to analysts’ expectations of $6.06 million. Blueprint Medicines Corp. had a negative net margin of 270.30% and a negative return on equity of 55.22%. The firm’s revenue for the quarter was up 79.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.47) earnings per share. Equities research analysts expect that Blueprint Medicines Corp. will post ($2.77) earnings per share for the current fiscal year.

WARNING: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/30/blueprint-medicines-corp-bpmc-receives-outperform-rating-from-wedbush.html.

In other news, Director Daniel Lynch sold 21,800 shares of the firm’s stock in a transaction on Thursday, October 13th. The shares were sold at an average price of $30.02, for a total transaction of $654,436.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 3.93% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BPMC. California State Teachers Retirement System increased its position in Blueprint Medicines Corp. by 0.7% in the third quarter. California State Teachers Retirement System now owns 42,262 shares of the company’s stock worth $1,255,000 after buying an additional 300 shares in the last quarter. BlackRock Investment Management LLC increased its position in Blueprint Medicines Corp. by 0.4% in the third quarter. BlackRock Investment Management LLC now owns 77,368 shares of the company’s stock worth $2,298,000 after buying an additional 332 shares in the last quarter. BlackRock Group LTD increased its position in Blueprint Medicines Corp. by 12.4% in the third quarter. BlackRock Group LTD now owns 7,857 shares of the company’s stock worth $234,000 after buying an additional 865 shares in the last quarter. UBS Asset Management Americas Inc. increased its position in Blueprint Medicines Corp. by 9.1% in the third quarter. UBS Asset Management Americas Inc. now owns 11,015 shares of the company’s stock worth $327,000 after buying an additional 915 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Blueprint Medicines Corp. by 1.2% in the first quarter. JPMorgan Chase & Co. now owns 80,175 shares of the company’s stock worth $1,447,000 after buying an additional 925 shares in the last quarter. Institutional investors and hedge funds own 73.05% of the company’s stock.

Blueprint Medicines Corp. Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

5 Day Chart for NASDAQ:BPMC

Receive News & Stock Ratings for Blueprint Medicines Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp. and related stocks with our FREE daily email newsletter.